Diagnostic tools company Prescient Medicine Holdings Inc disclosed on Tuesday the completion of the acquisition of AutoGenomics Inc for an undisclosed amount.

Based in the US, AutoGenomics Inc is a molecular diagnostics company that has developed and commercialised the INFINITI platform, a 510(k) exempt, automated, microarray-based multiplexing diagnostic system for personalised medicine, pain management, cardiovascular health, mental health, women's health, oncology, infectious diseases and genetic disorders.

Following the acquisition of AutoGenomics, Prescient Medicine will now advance the development and commercialisation of the INFINITI Neural Response Panel, a novel diagnostic test for the identification of patients who may be at risk for opioid use disorder (OUD), through the US FDA's de Novo premarket submission.

In conjunction with the acquisition, Prescient Medicine will market the INFINITI Neural Response Panel as LifeKit Predict to provide physicians with objective information to help assess the risk of developing an addiction to oral opioids.

The acquisition provides Prescient Medicine with access to the entire INFINITI product portfolio including the suite of INFINITI analyzers and a menu of over 65 molecular diagnostic tests across critical disease indications, which will complement Prescient Medicine's LifeKit product line of diagnostics.